Location of Repository

Deciphering the Kynurenine-3-Monooxygenase Interactome

By Mathuravani Aaditiyaa Thevandavakkam


Kynurenine-3-monooxygenase (KMO) is a mitochondrial enzyme in the kynurenine pathway (KP) through which tryptophan is degraded to NAD+. The central KP is altered in neurodegenerative diseases and other CNS disorders. The causative role of KP metabolites has been particularly well studied in the neurodegenerative disorder Huntington’s disease (HD), a fatal adult onset condition inherited in an autosomal dominant manner. In HD, flux in the KP is perturbed such that neurotoxic metabolites (3-hydroxykynurenine and quinolinic acid) of the pathway are increased relative to a neuroprotective metabolite (kynurenic acid). KMO lies at a critical branching point in the KP such that inhibition of KMO activity ameliorates this metabolic perturbation. Consequently, several recent studies have found that KMO inhibition is protective in models of HD. These findings have widespread implications in treating several neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease where the KP is implicated in pathogenesis. The focus of this project was to better understand the cellular role(s) and interactions of KMO. To this end, a novel membrane yeast two hybrid approach was established and optimised to identify protein interaction partners for outer mitochondrial membrane proteins. This approach was implemented to identify protein interaction partners of human KMO and its yeast orthologue Bna4, which were confirmed by biochemical approaches. Additionally, genetic interaction partners of BNA4 identified by systematic genetic screens were individually validated by classic genetic manipulations. Bioinformatic tools were then used to identify enriched interaction networks for KMO using this novel interaction data. These analyses suggested possible roles for KMO in many processes, including energy metabolism, cytoskeleton organisation and response to infection and inflammation, providing evidence that KMO plays roles in diverse cellular pathways in addition to the KP

Publisher: University of Leicester
Year: 2011
OAI identifier: oai:lra.le.ac.uk:2381/10070

Suggested articles



  1. (1988). 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims.
  2. (2003). 3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease?
  3. (1999). 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum.
  4. (1997). 4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes.
  5. (2004). A brilliant monomeric red fluorescent protein to visualize cytoskeleton dynamics in Dictyostelium.
  6. (1998). A genetic system based on split-ubiquitin for the analysis of interactions between membrane proteins in vivo.
  7. (1993). A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro3-hydroxyanthranilate.
  8. (2001). A novel approach for the identification of protein-protein interaction with integral membrane proteins.
  9. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.
  10. (1989). A novel genetic system to detect protein-protein interactions.
  11. (2009). A switch in retrograde signaling from survival to stress in rapid-onset neurodegeneration.
  12. (1999). A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.
  13. (2000). Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation.
  14. (2000). Accessory factors in clathrin-dependent synaptic vesicle endocytosis.
  15. (2011). Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.
  16. (2002). Aerobic and anaerobic NAD+ metabolism in Saccharomyces cerevisiae.
  17. (2002). An alternative strategy to determine the mitochondrial proteome using sucrose gradient fractionation and 1D PAGE on highly purified human heart mitochondria.
  18. (2000). An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype.
  19. (1998). Apoptosis: basic mechanisms and implications for cardiovascular disease.
  20. (2000). Approaches to detecting false positives in yeast two-hybrid systems.
  21. (2004). Assembling the mitochondrial outer membrane.
  22. (1982). Basal ganglia degeneration, myelin alterations, and enzyme inhibition induced in mice by the plant toxin 3-nitropropanoic acid.
  23. (2005). Beta-secretase-cleaved amyloid precursor protein accumulates at actin inclusions induced in neurons by stress or amyloid beta: a feedforward mechanism for Alzheimer's disease.
  24. (2004). Biochemical and phenotypic abnormalities in kynurenine aminotransferase IIdeficient mice.
  25. (2009). Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists.
  26. (2009). Biological pathway analysis by ArrayUnlock and Ingenuity Pathway Analysis.
  27. (2002). Blue Native electrophoresis to study mitochondrial and other protein complexes.
  28. (1981). Brain levels of neuron-specific and nonneuronal enolase in Huntington's disease.
  29. (1988). Brain quinolinic acid in Huntington's disease.
  30. (2002). Bridging structural biology and genomics: assessing protein interaction data with known complexes.
  31. (1997). C-Myc expression and its role in patients with chronic aortic regurgitation.
  32. (2010). Carbonyl reductase 1 protects pancreatic beta-cells against oxidative stress-induced apoptosis in glucotoxicity and glucolipotoxicity.
  33. (2007). Carbonyl reductases: the complex relationships of mammalian carbonyland quinone-reducing enzymes and their role in physiology.
  34. (2003). Characterization of the human heart mitochondrial proteome.
  35. (2003). Clathrin-mediated endocytosis in AP-2-depleted cells.
  36. (1997). Cofilin undergoes rapid dephosphorylation in stimulated neutrophils and translocates to ruffled membranes enriched in products of the NADPH oxidase complex. Evidence for a novel cycle of phosphorylation and dephosphorylation.
  37. (2007). Cofilin-mediated neurodegeneration in Alzheimer's disease and other amyloidopathies.
  38. (2006). Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations.
  39. (2010). Conserved elements associated with ribosomal genes and their trans-splice acceptor sites in Caenorhabditis elegans.
  40. (2003). Copper blocks quinolinic acid neurotoxicity in rats: contribution of antioxidant systems.
  41. (2005). Cortical cholinergic transmission and cortical information processing in schizophrenia.
  42. (2010). Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia.
  43. (2000). Decreased expression of striatal signaling genes in a mouse model of Huntington's disease.
  44. (2007). Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease.
  45. (2011). Dendritic spine loss and neurodegeneration is rescued by Rab11 in models of Huntington's disease.
  46. (1983). Differential vulnerability of central neurons of the rat to quinolinic acid.
  47. (2009). Disruption of Rab11 activity in a knock-in mouse model of Huntington's disease.
  48. (2001). Distinct behavior of mutant triosephosphate isomerase in hemolysate and in isolated form: molecular basis of enzyme deficiency.
  49. (1993). Distribution of c-myc oncoprotein in healthy and atherosclerotic human carotid arteries.
  50. (2007). Dopamine receptor activation reveals a novel, kynurenatesensitive component of striatal N-methyl-D-aspartate neurotoxicity.
  51. (1993). Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells.
  52. (2007). Dynamic rerouting of the carbohydrate flux is key to counteracting oxidative stress.
  53. (2005). Dynein mutations impair autophagic clearance of aggregate-prone proteins.
  54. (2002). Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain.
  55. (2001). Early and progressive accumulation of reactive microglia in the Huntington disease brain.
  56. (2000). Early kynurenergic impairment in Huntington's disease and in a transgenic animal model.
  57. (2009). Effect of indoleamine dioxygenase1 deficiency and kynurenine pathway inhibition on murine cerebral malaria.
  58. (1995). Effects of striatal excitotoxicity on huntingtin-like immunoreactivity.
  59. (2006). Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice.
  60. (2005). Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia.
  61. (2006). Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
  62. (2003). Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis.
  63. (1994). Excitotoxicity. Experimental correlates to human epilepsy.
  64. (1996). Exogenous glutamate concentration regulates the metabolic fate of glutamate in astrocytes.
  65. (2005). Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity.
  66. (2004). Expression of the receptor for advanced glycation end products in Huntington's disease caudate nucleus.
  67. (1990). Extraneural metabolism in early Huntington's disease.
  68. (1991). Factors associated with slow progression in Huntington's disease.
  69. (2006). From genomics to chemical genomics: new developments in KEGG.
  70. (1995). Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia.
  71. (1999). Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis.
  72. (2010). Functional gene expression profiling in yeast implicates translational dysfunction in mutant huntingtin toxicity.
  73. (2004). Gelsolin superfamily proteins: key regulators of cellular functions.
  74. (1993). Glutamate and glutamine metabolism and compartmentation in astrocytes.
  75. (2010). Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients.
  76. (1996). HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription.
  77. (1985). Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme.
  78. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series.
  79. (2007). Huntingtin interacting proteins are genetic modifiers of neurodegeneration.
  80. (2003). Huntingtin proteolysis in huntington disease. Clinical neuroscience research,
  81. (2008). Huntingtin-associated protein-1 is a modifier of the ageat-onset of Huntington's disease.
  82. (1997). Huntington's disease and dentatorubral-pallidoluysian atrophy: proteins, pathogenesis and pathology.
  83. (2009). Huntington's disease: the case for genetic modifiers.
  84. (1996). Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine.
  85. (2003). Identification of novel ErbB3-interacting factors using the split-ubiquitin membrane yeast two-hybrid system.
  86. (2007). Imaging microglial activation in Huntington's disease.
  87. (2003). Immune activation and degradation of tryptophan in coronary heart disease.
  88. (1992). Immunohistochemical localization of carbonyl reductase in human tissues.
  89. (2010). Impaired Kynurenine Pathway Metabolism in The Prefrontal Cortex of Individuals With Schizophrenia. Schizophr Bull.
  90. (1999). Impaired synaptic plasticity in mice carrying the Huntington's disease mutation.
  91. (1992). Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease.
  92. (1990). Increased cerebrospinal fluid quinolinic acid, kynurenic acid, and L-kynurenine in acute septicemia.
  93. (2002). Increased sensitivity to Nmethyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease.
  94. (2007). Inflammation, depression and dementia: are they connected?
  95. (2005). Inhibition of Alzheimer's amyloid-beta peptide-induced reduction of mitochondrial membrane potential and neurotoxicity by gelsolin.
  96. (1999). Interferon-gamma-dependent/independent expression of indoleamine 2,3-dioxygenase. Studies with interferon-gamma-knockout mice.
  97. (1990). Intracerebroventricular injection of kynurenic acid, but not kynurenine, induces ataxia and stereotyped behavior in rats.
  98. (2010). KEGG for representation and analysis of molecular networks involving diseases and drugs.
  99. (2000). KEGG: kyoto encyclopedia of genes and genomes.
  100. (1984). Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid.
  101. (2001). Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia.
  102. (2011). Kynurenine 3-monooxygenase (KMO) polymorphisms in schizophrenia: An association study. Schizophr Res.
  103. (1994). Kynurenine in blood plasma and DST in patients with endogenous anxiety and endogenous depression.
  104. (2009). Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis.
  105. (2001). Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection.
  106. (1994). Kynurenine pathway metabolites in cerebrospinal fluid and serum in complex partial seizures.
  107. (1998). L-kynurenine 3-monooxygenase from mitochondrial outer membrane of pig liver: purification, some properties, and monoclonal antibodies directed to the enzyme.
  108. (2005). Large-scale identification of yeast integral membrane protein interactions.
  109. (2007). Mapping protein-protein interactions for the yeast ABC transporter Ycf1p by integrated splitubiquitin membrane yeast two-hybrid analysis.
  110. (2002). Measuring beta-galactosidase activity in bacteria: cell growth, permeabilization, and enzyme assays in 96-well arrays.
  111. (1991). Membrane insertion of uracil permease, a polytopic yeast plasma membrane protein.
  112. (2010). Metallothioneins and copper metabolism are candidate therapeutic targets in Huntington's disease.
  113. (2006). Microglial activation correlates with severity in Huntington disease: a clinical and PET study.
  114. (2007). Microglial activation in presymptomatic Huntington's disease gene carriers.
  115. (2007). Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
  116. (2007). Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain.
  117. (2000). Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts.
  118. (2002). Mitochondrial oxidative stress and cell death in astrocytes--requirement for stored Ca2+ and sustained opening of the permeability transition pore.
  119. (1993). Mitotic stability and meiotic variability of the (CAG)n repeat in the Huntington disease gene.
  120. (1994). Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase.
  121. (1977). Molecular properties of L-kynurenine 3-hydroxylase from rat liver mitochondria.
  122. (1994). Movement disorder following excitotoxin lesions in primates.
  123. (2011). Mutant Huntingtin Causes Defective Actin Remodeling During Stress: Defining a New Role for Transglutaminase 2 in Neurodegenerative Disease. Hum Mol Genet.
  124. (2009). Mutant huntingtin impairs vesicle formation from recycling endosomes by interfering with Rab11 activity.
  125. (1996). Mutation of the Rab6 homologue of Saccharomyces cerevisiae, YPT6, inhibits both early Golgi function and ribosome biosynthesis.
  126. (2007). N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease.
  127. (2006). Natural isolates of Saccharomyces cerevisiae display complex genetic variation in sporulation efficiency.
  128. (1987). Nature and distribution of brain lesions in rats intoxicated with 3-nitropropionic acid: a type of hypoxic (energy deficient) brain damage.
  129. (2004). Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease.
  130. (2000). Neurodegenerative stimuli induce persistent ADF/cofilin-actin rods that disrupt distal neurite function.
  131. (2006). Neuronal and astrocytic shuttle mechanisms for cytosolic-mitochondrial transfer of reducing equivalents: current evidence and pharmacological tools.
  132. (1998). Neuronal death in cultured murine cortical cells is induced by inhibition of GAPDH and triosephosphate isomerase.
  133. (1993). Neuropharmacology of quinolinic and kynurenic acids.
  134. (1999). Neuroprotective effects of gelsolin during murine stroke.
  135. (2006). Neuroprotective role for carbonyl reductase?
  136. (1996). New insights into the compartmentation of glutamate and glutamine in cultured rat brain astrocytes.
  137. (2007). Normal platelet mitochondrial complex I activity in Huntington's disease.
  138. (2003). Overexpression and nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase in a transgenic mouse model of Huntington's disease.
  139. (2005). Peptide motifs: building the clathrin machinery.
  140. (2005). Pex3p initiates the formation of a preperoxisomal compartment from a subdomain of the endoplasmic reticulum in Saccharomyces cerevisiae.
  141. (1983). Pharmacology and regional variations of quinolinic acid-evoked excitations in the rat central nervous system.
  142. (1987). Plasmid construction by homologous recombination in yeast.
  143. (2009). Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia.
  144. (2005). Protein degradation and aging.
  145. (1995). Protein-protein interactions: methods for detection and analysis.
  146. (1972). Purification and properties of rat liver tryptophan oxygenase.
  147. (1983). Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain.
  148. (2002). Rapid turnover of actin in dendritic spines and its regulation by activity.
  149. (2004). Recent developments in the analysis of protein complexes.
  150. (2003). Reconstructing eukaryotic NAD metabolism.
  151. (1987). Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease.
  152. (2001). Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer's disease and in Huntington's disease fibroblasts.
  153. (1991). Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington's disease.
  154. (1982). Regulation of amino acid and nucleotide biosynthesis in yeast,
  155. (1972). Regulatory properties of hepatic tryptophan oxygenase.
  156. (1997). RIC1, a novel gene required for ribosome synthesis in Saccharomyces cerevisiae.
  157. (1999). Role of dynactin in endocytic traffic: effects of dynamitin overexpression and colocalization with CLIP-170.
  158. (2006). Screening for genetic modifiers of amyloid toxicity in yeast.
  159. (1999). Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology.
  160. (2002). Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer.
  161. (2001). SHIRPA, a protocol for behavioral assessment: validation for longitudinal study of neurological dysfunction in mice.
  162. (1978). Some factors influencing the neurotoxicity of intrastriatal injections of kainic acid.
  163. (2002). Specific modification of mitochondrial protein thiols in response to oxidative stress: a proteomics approach.
  164. (1992). Structure and function of actin.
  165. (2010). Structure, expression, and function of kynurenine aminotransferases in human and rodent brains.
  166. (1984). Studies on the disposition of quinolinic acid after intracerebral or systemic administration in the rat.
  167. (2006). Synthetic genetic array analysis in Saccharomyces cerevisiae.
  168. (2005). Synthetic lethality of retinoblastoma mutant cells in the Drosophila eye by mutation of a novel peptidyl prolyl isomerase gene.
  169. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.
  170. (2010). Targeting Kynurenine 3-Monooxygenase (KMO): Implications for Therapy in Huntington's Disease.
  171. (1997). The actin-severing protein gelsolin modulates calcium channel and NMDA receptor activities and vulnerability to excitotoxicity in hippocampal neurons.
  172. (2001). The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.
  173. (2008). The chemical genomic portrait of yeast: uncovering a phenotype for all genes.
  174. (2002). The clinical significance of cerebrospinal fluid levels of kynurenine pathway metabolites and lactate in severe malaria.
  175. (2001). The complex and intriguing lives of PIP2 with ion channels and transporters. Sci STKE,
  176. (2005). The concept of synthetic lethality in the context of anticancer therapy.
  177. (1993). The distribution of GABAA-benzodiazepine receptors in the basal ganglia in Huntington's disease and in the quinolinic acid-lesioned rat.
  178. (1995). The essential yeast NLT1 gene encodes the 64 kDa glycoprotein subunit of the oligosaccharyl transferase.
  179. (2010). The genetic landscape of a cell.
  180. (2004). The kynurenine pathway of tryptophan degradation as a drug target.
  181. (1990). The mitochondrial protein import apparatus.
  182. (2002). The neuropathology of Huntington's disease.
  183. (2001). The role of group I and group II metabotropic glutamate receptors in modulation of striatal NMDA and quinolinic acid toxicity.
  184. (2007). The supramolecular assemblies of voltage-dependent anion channels in the native membrane.
  185. (1997). The Tom and Tim machine.
  186. (1997). The vessel wall reaction in restenosis.
  187. (2005). The yeast split-ubiquitin system to study chloroplast membrane protein interactions.
  188. (1999). Three new dominant drug resistance cassettes for gene disruption in Saccharomyces cerevisiae.
  189. (1993). Trinucleotide repeat length instability and age of onset in Huntington's disease.
  190. (1988). Tryptophan degradation in patients infected by human immunodeficiency virus.
  191. (2006). Tryptophan metabolism and oxidative stress in patients with chronic brain injury.
  192. (2005). Tryptophan metabolism and oxidative stress in patients with Huntington's disease.
  193. (1998). Twodimensional electrophoresis of human placental mitochondria and protein identification by mass spectrometry: toward a human mitochondrial proteome.
  194. (2000). Use of Gprotein fusions to monitor integral membrane protein-protein interactions in yeast.
  195. (2005). Utilizing the split-ubiquitin membrane yeast two-hybrid system to identify protein-protein interactions of integral membrane proteins. Sci STKE,
  196. (2004). Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset.
  197. (2001). Versatility of the mitochondrial protein import machinery.
  198. (2006). wasted away, a Drosophila mutation in triosephosphate isomerase, causes paralysis, neurodegeneration, and early death.
  199. (2003). Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alphasynuclein.
  200. (1999). Yeast Two-Hybrid: State of the Art.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.